CareersInvestor RelationsPress RoomCOVID-19
Login
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases & Conditions
  4. Monoclonal Gammopathies
  5. MGUS & progression to Multiple Myeloma

The only Free Light Chain assay with FDA clearance for evaluation of MGUS

The Siemens Healthineers N Latex FLC Assay is FDA cleared for the Evaluation of patients with MGUS*

Free light chains, kappa (κ) lambda (λ), are produced by plasma cells and known to be an important marker in patients with Multiple Myeloma and AL Amyloidosis. The precursor condition to Multiple Myeloma is called Monoclonal Gammopathy of Undetermined Significance (MGUS) and although these individuals are not immediately treated, they are closely monitored due to their risk of progression to Multiple Myeloma.8

Webinar: Evaluating MGUS with Free Light Chain Assays in Clinical Practice

We invite you to view our webinar with Dr. John Mitsios, PhD, as he discusses the potential clinical usage of the N-Latex FLC assay in evaluation of MGUS.

Learning Objectives:

  • Define multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS)
  • Describe the clinical criteria used to define multiple myeloma
  • Describe the use of free light chains in the evaluation of MGUS
FLC ABC

    The N-Latex FLC Assay Difference

    The N Latex FLC assay for Free Light Chains uses multiple monoclonal antibodies for detection and is reported to have no false positive κ/λ ratios in patients with renal impairment5-7. Since renal impairment may confound MGUS diagnosis, the low false positive rate of the N Latex FLC assay compared to other assays 5-7 provides confidence that abnormal FLC ratio is truly due to a monoclonal disorder.

    The N-Latex FLC Difference

    Siemens N Latex FLC

    The FLC Competition

    More consistent results (Multi-Monoclonal antibody based)

    More variability (and drift, polyclonal antibodies)

    Guideline recommended technology (nephelometry)

    Assay is mentioned in the IMWG Guidelines, but the technology (turbidimetry) is not

    NO unnecessary bone marrow biopsies (no false positives)

    Unnecessary bone marrow biopsies (false positives) leading to patient discomfort and extra cost

    FDA cleared for the largest population precursor disease – MGUS

    Not FDA Cleared for evaluation of MGUS

    Cost efficiencies – order what you need
    Options for Automated and standalone

    Wasted reagents – bundled kit

    By clicking Submit you consent to the processing of your above given personal data by the Siemens Healthineers company referred to under Corporate Information and for the purpose described above. Further information concerning the processing of your data can be found in the Data Privacy Policy. You are aware that you can partially or completely revoke this consent at any time for the future. Please declare your revocation to the contact address given in the Corporate Information and sent it to us via the following e-mail address: dataprivacy.func@siemens-healthineers.com

    *in addition to diagnosis and monitoring of patients with Multiple Myeloma and diagnosis of patients with AL Amyloidosis

    1

    Kyle et. al. NEJM 2006

    2

    Seer.cancer.gov 2021

    3

    Rajkumar et. al. Blood 2005

    4

    Gran et. al. Am J. Hematol. 2021

    5

    Jacobs et. al. Clin Chem Lab Med 2014

    6

    Rindlisbacher et. al. J Applied Lab Med 2020

    7

    Sprangers et. al. Kidney International Reports 2020

    8

    Kyle et. Al. Leukemia 2010